Muscle-directed Therapy Apitegromab Put on FDA’s Fast Track

Muscle-directed Therapy Apitegromab Put on FDA’s Fast Track

295107

Muscle-directed Therapy Apitegromab Put on FDA’s Fast Track

Apitegromab, Scholar Rock’s muscle-directed therapy for spinal muscular atrophy (SMA), was granted a fast track designation by the U.S. Food and Drug Administration. “We are delighted to receive Fast Track designation and look forward to working closely with the FDA towards our aim of establishing apitegromab as the potential first muscle-directed therapy for patients with SMA,” Tony Kingsley, company president and CEO, said in a press release. Fast track designation is intended to accelerate a…

You must be logged in to read/download the full post.